Title |
Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies
|
---|---|
Published in |
Annals of Hematology, August 2018
|
DOI | 10.1007/s00277-018-3482-7 |
Pubmed ID | |
Authors |
Xiao-Ning Gao, Ji Lin, Shu-Hong Wang, Wen-Rong Huang, Fei Li, Hong-Hua Li, Jing Chen, Li-Jun Wang, Chun-Ji Gao, Li Yu, Dai-Hong Liu |
Abstract |
Unmanipulated haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) has been an established treatment to cure high-risk leukemia/lymphoma. Relapse is the main cause of treatment failure for patients with relapsed/refractory disease or with very high-risk gene mutations such as TP53, TET2, and DNMT3a. In this study, we aimed to establish the tolerance and efficacy of prophylactic donor lymphocyte infusion (DLI) with G-CSF-primed peripheral blood progenitors for prevention of relapse in these very high-risk patients after haplo-PBSCT. The prophylactic DLI was given at a median of 77 days after transplantation in 31 of 45 consecutive patients with very high-risk leukemia/lymphoma. The median dose of CD3+ cells for infusion was 1.8 × 107/kg. The 100-day incidences of acute graft-versus-host disease (GVHD) grades 2-4 and 3-4 after DLI were 55.3% and 10.2%. The 2-year incidences of chronic GVHD and severe chronic GVHD were 52.0% and 18.2%. The 2-year incidences of non-relapse mortality and relapse were 33.1% and 32.5%. The 2-year probabilities of overall survival and relapse-free survival were 40.1% and 31.9%. Poor-risk gene mutations (p = 0.029), disease in non-remission status prior to transplantation (p = 0.005), and donors older than 40 years of age (p = 0.043) were associated with relapse after DLI. In multivariate analysis, disease in non-remission status prior to transplantation was an independent risk factor of relapse (hazard ratio = 4.079; p = 0.035). These data showed the feasibility of the prophylactic DLI in the haplo-PBSCT setting and the anti-leukemic efficacy in very high-risk leukemia/lymphoma. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 34 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 6 | 18% |
Other | 3 | 9% |
Student > Master | 3 | 9% |
Student > Ph. D. Student | 2 | 6% |
Student > Doctoral Student | 1 | 3% |
Other | 2 | 6% |
Unknown | 17 | 50% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 7 | 21% |
Biochemistry, Genetics and Molecular Biology | 3 | 9% |
Immunology and Microbiology | 2 | 6% |
Nursing and Health Professions | 1 | 3% |
Philosophy | 1 | 3% |
Other | 3 | 9% |
Unknown | 17 | 50% |